Clinical trial
Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent…
NCT00248833 · U.S. Army Medical Research and Development Command, U.S. Fed · Completed
Key facts
| NCT number | NCT00248833 |
|---|---|
| Title | Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis. |
| Official title | Phase 1 Dose Esc Study of Safety and Immun of 3 Injections, Given at 0, 6 and 24 Wks, of Grp B Meningococcal 44/76 MOS NOMV 5D Vaccine Admin to Healthy Subjs IM With and Without Adjuvant |
| Lead sponsor | U.S. Army Medical Research and Development Command, U.S. Fed |
| Collaborators | Walter Reed Army Institute of Research (WRAIR) U.S. Fed |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Meningitis, Meningococcal, Serogroup B |
| Intervention type | Biological |
| Interventions | 25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine, 50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine |
| Enrollment | 34 |
| Start date | Dec 5, 2005 |
| Primary completion | Nov 30, 2006 |
| Completion | Dec 1, 2007 |
| First posted | Nov 4, 2005 |
| Last update posted | Oct 29, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: